HOME >> BIOLOGY >> NEWS
Remicade therapy shown to improve productivity in patients treated for chronic plaque psoriasis

WASHINGTON, D.C., February 2, 2007 -- Investigators reported today at the American Academy of Dermatology annual meeting that patients with moderate to severe plaque psoriasis receiving REMICADE (infliximab) induction and maintenance therapy experienced significant improvements in productivity at week 10, which were sustained through week 50. After 10 weeks, patients receiving REMICADE 3 mg/kg or 5 mg/kg achieved significant improvements in work and daily activities (2.9 and 3.1, respectively, from baseline) compared to little to no improvement (a mean decrease of 0.1) among placebo-treated patients (P < 0.001), as measured by the Productivity Visual Analogue Scale. Psoriasis is an inflammatory disorder characterized by raised, inflamed, red lesions, or plaques, which can cause physical pain and emotional distress. It is estimated that as many as 7.5 million people in the U.S. have psoriasis, which can present in various forms and can range from mild to severe and disabling.

"These findings show a relationship between the significant improvements REMICADE-treated patients experienced in psoriasis and improvements in productivity," said Steven Feldman, M.D., Ph.D., professor of dermatology, pathology and public health sciences, Bowman Gray School of Medicine, Wake Forest University. "Such analyses offer further insight into the impact of this chronic inflammatory disease on patient productivity and the effect of intervening with an appropriate biologic treatment, like REMICADE. We look forward to further studies to identify the economic implications of such productivity analyses in a real-world setting."

In the Evaluation of Infliximab for Psoriasis in a [REMICADE] Efficacy and Safety Study (EXPRESS II), REMICADE-treated patients demonstrated a statistically significant productivity increase of 2.9 and 3.1 in the 3 mg/kg and 5 mg/kg groups, respectively, from baseline compared with a mean decrease of 0.1 with placebo as measured by the
'"/>

Contact: Brian Kenney
215-620-0111
Centocor, Inc.
2-Feb-2007


Page: 1 2 3 4

Related biology news :

1. Remicade data in ankylosing spondylitis show improvement in spinal mobility and spinal inflammation
2. Long-term ulcerative colitis study shows Remicade responders maintained improvement
3. New analyses reinforce efficacy of Remicade in treatment of severe psoriasis
4. Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
5. Testosterone replacement therapy: How safe for aging men?
6. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
7. Aggressive therapy best for certain AML patients
8. Under magnetic force, nanoparticles may deliver gene therapy
9. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Stem cell therapy rescues motor neurons in ALS model
11. Study identifies new gene therapy tools for inherited blindness

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/12/2020)... ... 12, 2020 , ... Mosio recently announced its newly updated ... agencies of all sizes. With a focus on tracking symptoms and monitoring outbreaks ... care, Mosio helps public health departments automate communications and provide more personalized care ...
(Date:7/31/2020)... FREDERICK, Md. (PRWEB) , ... July 30, 2020 ... ... Business Innovation Research (SBIR) Phase II contract awarded by the Joint Science & ... goal of this project is to develop, optimize, and scale-up a highly efficient ...
(Date:7/10/2020)... ... July 08, 2020 , ... Overcoming Comparability Issues in Regenerative ... Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy ... effective way to complete one? Will the study comply with all FDA requirements? ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing ... announced that they have entered into a strategic partnership whereby Catalent will provide ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... 200 of the top radiation centers in 16 countries, has reached its 20th ... SDX® is now in routine use at top universities including University of Pennsylvania, ...
(Date:7/22/2020)... ... ... Join experts from Reed Tech , Gary Saner, Sr. Manager, Information Solutions Life ... webinar on Thursday, August 13, 2020 at 11am EDT (4pm BST/UK). , The ... medical devices, the NMPA has departments dealing with medical device registration (pre-market approvals) and ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... “We are ... Third Wave Bioactives. “It’s the only technology of its kind on the market and ... of onions with the protective capacity of traditional cultured ingredients, creating a natural way ...
Breaking Biology Technology:
Cached News: